Outcome of Board Meeting for Audited Financial Results for the Quarter and Year Ended 31st March, 2026.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lincoln Pharmaceuticals reported FY26 standalone and consolidated net profit of Rs. 87.89 crore, up 6.74% from Rs. 82.35 crore in FY25. Revenue from operations grew 7.67% to Rs. 671.03 crore from Rs. 623.23 crore. EBITDA increased 5.78% to Rs. 131.14 crore from Rs. 123.97 crore. EPS stood at Rs. 43.88 per share. The Board recommended a dividend of 18% (Rs. 1.80 per share). The company aims to achieve Rs. 1,000 crore revenue in 3 years with 15-18% annual growth, focusing on cardiac, diabetic, dermatology, and ENT segments. FII holding increased to 5.20% from 5.00%. Statutory auditors issued an unmodified (clean) opinion on the financial statements.
The company delivered steady growth with clean audit opinion and dividend declaration. PAT growth of 6.74% is positive but below 25% threshold. Revenue growth of 7.67% is below 20% threshold. The company has no debt, positive operating cash flow, and adequate financial health, which are positive signals for shareholders.